Lila Sciences Raises $350 Million in Series A Funding to Expand AI-Powered Research Platform

Lila Sciences, a biotechnology and artificial intelligence company based in Cambridge, Massachusetts, has raised $350 million in a Series A funding round.

The investment was co-led by Braidwell and Collective Global. Other participants included NVentures, Analog Devices, IQT, Dauntless Ventures, Catalio Capital Management, Pennant Investors, Flagship Pioneering, Altitude Life Science Ventures, General Catalyst, and the Abu Dhabi Investment Authority.

Funding to Support Platform Expansion

With this latest round, Lila Sciences has raised a total of $550 million to date.

The company plans to use the new capital to expand its automated AI Science Factories, enhance its multi-agent software platform, and strengthen its materials and chemical simulation capabilities. In addition, it aims to grow its engineering team across international markets.

Focus on Autonomous Scientific Research

Lila Sciences develops artificial intelligence systems designed to support scientific discovery. Its platform combines autonomous AI agents with laboratory automation to conduct experiments and analyze results.

The company focuses on applications across healthcare, energy, and defense. Its technology is designed to help researchers identify new molecular compounds and accelerate scientific workflows through automated experimentation.

Strategic Partnerships and Commercial Expansion

Led by co-founder and CEO Dr. Geoffrey von Maltzahn, Lila Sciences has also expanded its commercial activities.

Recently, the company entered strategic partnerships focused on national security technologies. It has also opened its autonomous platform architecture to its first group of enterprise customers as it continues to broaden commercial adoption of its technology.

Recently funded and expanding your team?
WorkNation helps startups and growth-stage companies hire top talent faster.
📩 hiring@worknation.buzz | 🌐 worknation.buzz/hiring-solutions